Vertex has just filed for approval of Kalydeco for CF patients aged 18 and older who have the R117H mutation, the most common residual function mutation, which could add another 300 patients to ...

Patients aged 6 years and older, weighing 25 kg or more, who have one of the following gating (class III) CFTR mutations: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R. Also for ...

Jan. 30, 2025 — A research group has developed new advanced light-controlled tools that enable precise control of proteins in real time in living cells. This groundbreaking research opens doors ...